EQ-5D-5L Update Reshapes Cancer Economics

Episode 14 — 28 May 2026 NICE's first QALY valuation update in over a decade shows cancer medicines becoming more cost-effective while quality-of-life therapies face higher ICERs. Meanwhile, JCA expansion into medical devices and new NICE prioritisation frameworks signal tighter evidence requirements across the board. Hosted by Marcus and Sara. Access Brief — Daily briefings on HEOR, HTA strategy and the evidence access landscape. Full transcript and sources at outcomes-analytica.no/podcast

Transcript

SPEAKER_00 0:00

Welcome to Access Brief, the daily AI podcast on HEAR, HTA, and Market Access. I'm Marcus with Sarah. Today, NICE's major EQ5 D5L consultation, reshaping cost effectiveness, CHMP approvals, including rare disease treatments, and JCA device expansion. Let's get into it.

SPEAKER_01 0:19

The NICE EQ5 D5L consultation is fascinating for what it reveals about embedded bias in our current framework. Their impact assessment of 37 published appraisals shows cancer medicines becoming more cost-effective with the new value set while quality of life only improving therapies. See a median 59% ICER increase.

SPEAKER_00 0:38

That's a predictable outcome when you are replacing 1990s data with contemporary health state valuations. But I'm more interested in the methodological implications. We're finally moving away from a value set that predates most modern therapeutic classes.

SPEAKER_01 0:54

Predictable, yes, but problematic from a portfolio strategy perspective. This isn't just a technical update, it's systematically advantaging oncology assets while penalizing quality of life interventions. Mental health, chronic pain management, rare disease symptomatic treatments, they're all getting squeezed.

SPEAKER_00 1:11

But that assumes the current valuations are correct. If contemporary patients genuinely value health states differently than they did 30 years ago, then these shifts reflect real preference changes, not arbitrary bias.

SPEAKER_01 1:24

Real preference changes influenced by what exactly? Societal attitudes, healthcare expectations? This consultation runs until May 27th, but I doubt NICE will address whether we're capturing genuine value evolution or just recalibrating to current therapeutic landscapes.

SPEAKER_00 1:40

Fair point, but we can't preserve outdated methodology just to protect certain therapeutic areas. The evidence base needs updating.

SPEAKER_01 1:47

Moving to CHMP approvals, they recommended eight medicines at their May meeting, including JASKIDE for idiopathic pulmonary fibrosis. Rare diseases with progressive deterioration like IPF represent exactly the kind of unmet need where traditional QALY calculations break down.

SPEAKER_00 2:04

IPF is a perfect example of where clinical urgency should drive approval decisions. Progressive lung scarring with limited treatment options, the evidence bar has to be different.

SPEAKER_01 2:15

But that's where I disagree. Clinical urgency doesn't automatically justify relaxed evidence standards. We've seen too many rare disease approvals based on surrogate endpoints that don't translate to meaningful patient outcomes.

SPEAKER_00 2:27

Naranda Melast went through standard CHMP review. They're not rubber stamping applications.

SPEAKER_01 2:33

Standard review, yes, but with implicit bias toward approval in rare diseases with high unmet need. The question is whether we're being rigorous enough about long-term benefit risk profiles.

SPEAKER_00 2:43

You're asking patients with progressive fatal conditions to wait for perfect evidence that may never come. Sometimes regulatory pragmatism is appropriate.

SPEAKER_01 2:52

The JCA expansion into medical devices starting June 2026 is where things get really complex. Class 2B and 3 devices joining oncology and ATMP assessments means we're applying pharmaceutical evidence frameworks to completely different innovation paradigms.

SPEAKER_00 3:08

The methodology guidance addresses evidence gaps, but you're right about paradigm mismatches. Device iterative improvement cycles don't align well with fixed assessment time points.

SPEAKER_01 3:18

Exactly. And with scientific advice slots capped at 17 total, 8, 12 medicines, 2, 5 medical devices, we're creating artificial scarcity and pre-submission guidance, right, when manufacturers need it most.

SPEAKER_00 3:30

That capacity constraint is telling. Either HTEC is under-resourced for the expanded scope, or they're deliberately limiting engagement to manage workload.

SPEAKER_01 3:39

I suspect both. But the real issue is whether device manufacturers will adapt their development strategies to JCA requirements, or simply avoid European markets where possible.

SPEAKER_00 3:49

Given the market size, avoidance isn't realistic. They'll adapt, but probably with increased development timelines and costs that ultimately affect innovation pace.

SPEAKER_01 3:59

NICE's new prioritization framework with monthly board meetings and unified guidance portfolio targeting NHS operational priorities is smart positioning. Focusing on digital mental health therapies for workforce constraints directly addresses system pressures.

SPEAKER_00 4:14

It's pragmatic, but I'm concerned about mission creep. When HTA bodies start prioritizing based on operational convenience rather than clinical value, we're moving away from evidence-based assessment.

SPEAKER_01 4:25

But clinical value in isolation from system capacity is meaningless. If the NHS can't implement guidance because of workforce constraints, what's the point of producing it?

SPEAKER_00 4:36

That's a resource allocation problem, not an HTA methodology problem. We shouldn't corrupt scientific assessment with operational expediency.

SPEAKER_01 4:45

The MHRA nice aligned pathway progressing toward June guidance will test exactly that tension. Faster approvals mean compressed evidence review cycles.

SPEAKER_00 4:55

True, but alignment could also mean more coherent regulatory HTA signal. We'll see whether speed comes at the expense of rigor.

SPEAKER_01 5:02

These developments collectively represent tighter evidence requirements, expanded EU scrutiny, and evolving value frameworks. Market access strategies need fundamental recalibration.

SPEAKER_00 5:14

Agreed. The EQ5 D5L update alone will reshape cost effectiveness models across multiple therapeutic areas. Combined with JCA device expansion and new prioritization approaches, we're looking at a significantly different access landscape.

SPEAKER_01 5:29

Back tomorrow on AccessBrief, show notes at outcomes analytica.no.